Labcorp Holdings Inc.

NYQ: LH
Live Quote

📈 ZcoreAI Score

Our AI model analyzes Labcorp Holdings Inc.'s price action across multiple timeframes using regression channels and statistical scoring.

Get LH Z-Score →

About Labcorp Holdings Inc.

Healthcare Diagnostics & Research
Labcorp Holdings Inc. provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations. In addition, the company offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; and Generative AI-enabled Test Selection, a generative AI-enabled tool. It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs. The company was founded in 1995 and is headquartered in Burlington, North Carolina.

📊 Fundamental Analysis

Labcorp Holdings Inc. demonstrates a profit margin of 6.3%, which is below the sector average, suggesting competitive pressure.

The company recently reported 5.6% revenue growth, which is modest compared to its industry peers.

Return on Equity (ROE) is 10.5%, which suggests room for improvement in capital utilization.

At a current price of $260.93, LH currently sits at the 61st percentile of its 52-week range (Range: $209.38 - $293.72).

💰 Valuation Insight

LH is valued broadly in line with the sector at a PE of 24.95. Analysts expect earnings growth, as indicated by a lower forward PE.

🏥 Financial Health

🔴 Profit Margin Weak
🔴 Debt/Equity Elevated
🔴 Revenue Growth Weak
🔴 Return on Equity Weak
⚠️ Beta (Risk) Moderate Volatility

Key Financials

Market Cap
$21.63B
Trailing P/E
24.95
Forward P/E
13.53
Beta (5Y)
0.98
52W High
$293.72
52W Low
$209.38
Avg Volume
677K
Day High
Day Low
Get LH Z-Score on Dashboard 🚀